Organon & Co. (OGN) Climbs 13.7% Ahead of Dividends

We recently published 10 Stocks Beating the Market with Eye-Popping Gains. Organon & Co. (NYSE:OGN) is one of the best-performing stocks on Monday.

Organon extended its winning streak to a third straight day on Monday, jumping 13.72 percent to close at $7.71 as investors snapped up shares ahead of the record date for its next quarterly dividend payment, despite weak earnings results for the third quarter.

In an updated report, Organon & Co. (NYSE:OGN) said it would distribute $0.02 worth of dividends to all common shareholders as of November 20, 2025, payable on December 11, 2025.

This followed the results of its earnings performance in the third quarter of the year, where it registered $160 million in net income, lower by 55 percent than the $359 million in the same period last year.

Revenues, on the other hand, inched up by 1 percent to $1.6 billion from $1.58 billion year-on-year, on the back of higher revenues from general medicines, which offset the drop in revenues from women’s health.

Following the results, Organon & Co. (NYSE:OGN) lowered its revenue guidance for full-year 2025 to a range of $6.2 billion to $6.25 billion from $6.275 billion to $6.375 billion previously.

Expectations for adjusted EBITDA margin were also reduced to 31 percent from up to 32 percent earlier.

Organon & Co. (NYSE:OGN) is a US-based global pharmaceutical company specializing in women’s health, biosimilars, and reproductive health, among others.

While we acknowledge the potential of OGN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.